COMPASS Pathways (NASDAQ:CMPS – Get Free Report) is expected to be posting its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect COMPASS Pathways to post earnings of ($0.40) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:00 AM ET.
COMPASS Pathways (NASDAQ:CMPS – Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
COMPASS Pathways Stock Down 2.5%
NASDAQ:CMPS opened at $6.34 on Thursday. The firm has a market capitalization of $608.26 million, a price-to-earnings ratio of -3.45 and a beta of 2.21. COMPASS Pathways has a twelve month low of $2.25 and a twelve month high of $7.09. The stock’s 50 day moving average price is $5.38 and its two-hundred day moving average price is $4.40. The company has a quick ratio of 8.82, a current ratio of 8.82 and a debt-to-equity ratio of 0.16.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of equities analysts recently weighed in on CMPS shares. Canaccord Genuity Group restated a “buy” rating and set a $15.00 target price on shares of COMPASS Pathways in a report on Friday, August 1st. HC Wainwright lowered their price objective on shares of COMPASS Pathways from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, August 4th. BTIG Research boosted their price objective on shares of COMPASS Pathways from $7.00 to $14.00 and gave the stock a “buy” rating in a research note on Monday, October 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.00.
Check Out Our Latest Report on CMPS
COMPASS Pathways Company Profile
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Featured Articles
- Five stocks we like better than COMPASS Pathways
- With Risk Tolerance, One Size Does Not Fit All
- Archer’s Recent String of Victories Signals a New Phase of Growth
- Best Energy Stocks – Energy Stocks to Buy Now
- 3 Key Stocks Boosting Buybacks Amid Improving Fundamentals
- How to Invest in Biotech Stocks
- The Best AI for Picking Stocks, Ranked by Performance
Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.